Fig. 6.

Dependence of CT’s therapeutic antitumor effect on T-cell-mediated immune defense. LLC-bearing C57BL/6 (8 weeks old, n = 5) mice were treated every other day with i.t. injection of CT (100 µg/mouse) and anti-PD-L1 (αPD-L1, 10 µg/mouse) alone or in combination starting on day 7. Rat IgG2b was used as the control antibody (Ctl Ab). a LLC tumors removed 24 h after the third treatment were dissociated into single-cell suspension, which were immunostained and analyzed for the abundance of various subsets of leukocytes. b RNA samples isolated from LLC tumors removed 24 h after the third treatment were quantitated for expression of indicated genes at the mRNA level by qPCR. Data in a, b are shown as the average (mean ± SD) of each group, with *p < 0.001 and **p < 0.0001 by t test. c LLC-bearing mice were additionally treated with i.p. injection of indicated 200 µg of leukocyte-depleting antibody once every 3 days, starting on day 5. Tumor size was monitored twice per week and tumor growth curve was plotted